STADA Arzneimittel AG
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From STADA Arzneimittel AG
Marketing applications for MenABCWY, zolbetuximab, crovalimab, macitentan/tadalafil, Coacillium, mRNA-1345, dasiglucagon and ustekinumab have been submitted to the European Medicines Agency for review.
Alvotech and Stada have indicated that they could receive an EMA opinion on their AVT04 Stelara biosimilar as early as the second half of 2023, after the agency confirmed acceptance of their ustekinumab filing.
The latest Generics Bulletin Top 50 ranking of global generics and biosimilars companies sees a new name in the top five amid transformations for some of the leading off-patent players. Meanwhile, a number of mid-level firms shift position and newcomers climb into the bottom of the table.
Roche is not disclosing Phase II results yet, but must exceed late-stage rival drug’s 50% reduction in protein build up to compete in immunoglobulin A nephropathy.
- Generic Drugs
- OTC, Consumer
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Bain Capital
- BIOCEUTICALS Arzneimittel AG
- Britannia Pharmaceuticals Limited
- Forum Bioscience Holdings, Ltd.
- Laboratorio Vannier S.A.
- Nidda Healthcare
- STADAPHARM GmbH
- LobSor Pharmaceuticals AB
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.